Immunotec announces investment by the Caisse de dépôt et placement du Quebec

MONTREAL, Oct. 25 /CNW Telbec/ - Immunotec Research Ltd. is pleased to
announce that the Caisse de dépôt et placement du Québec ("Caisse") has
acquired $9 million of equity interest in the Company from two of the
Company's principal shareholders.

As previously announced, Immunotec is also in the process of finalizing a
reverse take-over transaction with Magistral Biotech Inc. which will result in
the Company becoming publicly listed on the TSX Venture Exchange. Closing of
this transaction is expected to occur in December 2006.

"The investment by the Caisse marks an important milestone in the history
of our Company," stated Charles Roberts, President of Immunotec. "Having such
a solid partner provides us with the credibility, financial backing and
business network which will enable us to take Immunotec to even greater
heights. This event, coupled with our planned public listing, will
dramatically transform the profile of Immunotec."

About Immunotec Research Ltd.

Based in Vaudreuil-Dorion (Montreal), Quebec, Immunotec develops and
markets dietary supplements, vitamins, personal care products and natural
health products. Patented and backed by more than 20 years of research,
Immunotec's flagship product is Immunocal/HMS 90. Immunotec's products are
distributed and sold in Canada and in the United States through a network
marketing system, and in 22 other countries under exclusive distributorship

About the Caisse de dépôt et placement du Québec

The Caisse de dépôt et placement du Québec is a financial institution
that manages funds primarily for public and private pension and insurance
plans. As at December 31, 2005, it held $122.2 billion of net assets. The
Caisse invests in the main financial markets as well as in private equity and
real estate. Its private equity team focuses on companies with the potential
for strong growth and returns. The institution partners with dynamic companies
in various sectors, offering them a full range of debt and equity financing
products. As at December 31, 2005, the private equity portfolios held
$10.9 billion of net assets. For more information:

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.